Clinical trial · Observational
Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
NCT06474533CI-TRIAL-00124074recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize grade of glial neoplasms.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Intracranial Neoplasm | Intracranial Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fluorethyltyrosine (18-F) | Drug | — | UNRESOLVED |
| Positron Emission Tomography (PET) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Population 1: Participants with intracranial neoplasms
- description
- Participants with intracranial neoplasms (glial or metastatic disease) with concern for recurrence or progression on conventional imaging.
- interventionNames
- Drug: Fluorethyltyrosine (18-F)
- Procedure: Positron Emission Tomography (PET)
- label
- Population 2: Participants with suspected glial neoplasms
- description
- Participants with suspected glial neoplasms (Grade 2 - 4) planning to undergo biopsy or surgery prior to non-investigational, standard-of-care, primary treatment (radiation therapy and/or surgery)
- interventionNames
- Drug: Fluorethyltyrosine (18-F)
- Procedure: Positron Emission Tomography (PET)
Primary outcomes (3)
- measure
- Maximum Intracranial lesion tumor-to-background ratio (TBRmax)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 4 Years
Show eligibility criteria text
Inclusion Criteria:
* Presence or suspicion of intracranial neoplasm in two populations:
* Population 1: Participants after primary treatment (radiation therapy and/or surgery) with suspicion of recurrence on MRI.
* Three sub-populations will be considered:
* Recurrent metastatic lesions.
* Recurrent high-grade gliomas (Grades 3 and 4).
* Recurrent low-grade gliomas (Grade 2).
* Population 2: Participants prior to primary treatment with planned biopsy or surgical resection.
* Age \> 3 years.
Participants in other clinical trials will be eligible for this study including patients undergoing surgery guided by 5-aminolevulinic acid.
Exclusion Criteria:
* Participants with known incompatibility to PET or Computerized tomography (CT)/magnetic resonance imaging (MRI) scans.
* Participants unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation.
* Sedation or anesthesia can be used for participants who cannot tolerate the exam.References
Publications (0)
Data not yet available
No reference posted for this study.